mTOR as a Molecular Target in HPV-Associated Oral and Cervical Squamous Carcinomas

Alfredo A. Molinolo1, Christina Marsh1, Mohamed El Dinali4, Nitin Gangane3, Kaitlin Jennison1, Stephen Hewitt2, Vyomesh Patel1, Tanguy Y. Seiwert4, and J. Silvio Gutkind1

Abstract

Purpose: The incidence of head and neck squamous cell carcinomas (HNSCC) associated with human papillomavirus (HPV) infection has increased over the past decades in the United States. We aimed at examining the global impact of HPV-associated HNSCC and whether the established key role of mTOR activation in HNSCC is also observed in HPV+ HNSCC lesions, thereby providing novel treatment options for HPV-associated HNSCC patients.

Experimental Design: An international HNSCC tissue microarray (TMA) was used to analyze the expression of p16INK4A, a surrogate for HPV infection, and Akt-mTOR pathway activation. Results were confirmed in a large collection of HPV+ and HPV+ HNSCC cases and in a cervical cancer (CCSCC) TMA. Observations were validated in HNSCC and CCSCC-derived cell lines, which were xenografted into immunodeficient mice for tumorigenesis assays.

Results: Approximately 20% of all HNSCC lesions could be classified as HPV+, irrespective of their country of origin. mTOR pathway activation was observed in most HPV+ HNSCC and CCSCC lesions and cell lines. The preclinical efficacy of mTOR inhibition by rapamycin and RAD001 was explored in HPV+ HNSCC and CCSCC tumor xenografts. Both mTOR inhibitors effectively decreased mTOR activity in vivo and caused a remarkable decrease in tumor burden. These results emphasize the emerging global impact of HPV-related HNSCCs and indicate that the activation of the mTOR pathway is a widespread event in both HPV+ and HPV-associated HNSCC and CCSCC lesions.

Conclusions: The emerging results may provide a rationale for the clinical evaluation of mTOR inhibitors as a molecular targeted approach for the treatment of HPV-associated malignancies. Clin Cancer Res; 18(9); 2558–68. ©2012 AACR.

Introduction

The infection with human papillomavirus (HPV) is associated with benign and malignant tumors of the squamous epithelia (1). HPV types have been classified into low- or high-risk groups depending on their likelihood of inducing cervical cancer on persistent infection (1). Indeed, HPV is associated with nearly all cervical cancers, 70% of which are related to the high-risk HPV types 16 and 18 (1). HPV is also associated with other human malignancies and is now considered to represent the viral etiologic agent responsible for about 500,000 new annual human cancer cases worldwide, including those of the cervix, anus, vulva, penis, and of the oral cavity and pharynx (1, 2). In particular, for oral and pharyngeal cancers, these cancers, which are collectively referred to as head and neck squamous cell carcinomas (HNSCC; ref. 3), have been traditionally associated with tobacco and alcohol consumption in the Western world, with the added risk factor of areca nut in Asia (4). A role for papillomavirus in oral carcinogenesis has been recognized since the mid 80’s (5, 6), but the perception of an emerging epidemic of HPV-associated HNSCC is relatively recent (7, 8), with a highly significant increase in the incidence of oropharyngeal tumors, the most likely to be HPV associated, predominantly in younger patients (8). HPV-positive (HPV+) and HPV-negative (HPV-) oropharyngeal squamous-cell carcinomas might be inherently different, and hence have different causes, risk-factor profiles, and survival outcomes (9, 10). Indeed, there is a strong correlation between positive tumor HPV status and increased patient survival after surgical treatment (11), radiotherapy (12, 13), and combined treatment approaches (14–16). However, the overall global impact of HPV-associated HNSCC cases and the nature of the shared and distinct molecular
Translational Relevance

The emerging results may provide a rationale for the early evaluation of the clinical efficacy of mTOR inhibitors as a molecular targeted approach for the treatment of HPV-associated malignancies.

mechanisms underlying the progression of HPV\(^+\) and HPV\(^-\) HNSCC lesions are still unclear.

In this regard, the NIDCR-NCI spearheaded an international collaborative effort that resulted in the construction of a tissue microarray (TMA) with hundreds of samples of HNSCC from patients from 8 different countries from Asia, Africa, and America (17). This array provided an opportunity to examine the distribution of possible HPV-associated cases in each participating country, and thus afforded the first glimpse at the possible impact of HPV-associated HNSCC worldwide. As a general screening approach, we used in this array the expression of protein product of the \(p16\) tumor suppressor gene, referred herein as \(p16\), as a validated surrogate marker for HPV infections (18–20).

Nearly 20% of all cases were positive, with a limited country-specific distribution.

Among the multiple dysregulated signaling mechanism in HNSCC, we have documented that the vast majority of the HNSCC lesions exhibit activation of the Akt-mTOR signaling route (17), a central component of multiple growth promoting and metabolic pathways. Thus, the availability of these HNSCC tissue arrays provided an opportunity to examine whether HPV-associated HNSCC also involve Akt-mTOR activation, in spite of their distinct etiology. We observed that most \(p16\)-positive HNSCC cases exhibited a remarkable activation of the mTOR pathway, similar to HNSCC associated with more traditional risk factors. These observations were validated in a large collection of HNSCC cell lines and HNSCC cases of known HPV status and in a newly developed cervical cancer tissue array, thus confirming that HPV-associated SCCs display overactive mTOR pathway irrespective of their anatomic site of origin. These findings prompted us to explore the preclinical efficacy of mTOR inhibition in HPV\(^+\) oral and cervical tumor xenografts. We show here that 2 widely used mTOR inhibitors in the clinic, rapamycin and RAD001, effectively decrease mTOR activity \textit{in vivo}, and promote the rapid collapse of HPV-associated oral and cervical tumors, resulting in a remarkable decrease in tumor burden. Collectively, the emerging results may provide a rationale for the clinical evaluation of mTOR inhibitors as a molecular targeted approach for the treatment of HPV-associated malignancies.

Materials and Methods

Chemical, reagents, cell culture and Western blot analysis of Akt-mTOR pathway

All chemicals and reagents were from Sigma-Aldrich, unless indicated. HN12, HN13, and HN30 cells were obtained from Dr. J.F. Ensley (Wayne State University, Detroit, MI; ref. 21). Cal33, and Cal27 and HeLa cells were from DSMZ and American Type Culture Collection, respectively. UDSCC2, SCC47, SCC90, and 93VU147T cell lines were from Drs. Henning Bier, University of Duesseldorf; Thomas Carey, University of Michigan; Susan Gollin, University of Pittsburgh; and Steenbergen, VUMC, Netherlands; respectively. Spontaneously immortalized normal oral keratinocytes (NOKSI) were established as reported (22). All cells before experiments were authenticated by PCR amplification of short tandem repeats (Genetica DNA Laboratories, Inc.) to ensure cell identity. Detailed information of cell culture conditions, antibodies use throughout the study, and Western blot analysis of Akt-mTOR pathway in cell lysates (essentially as reported in ref. 23) are described in detail in Supplementary Material.

Assessment of genomic HPV status in HNSCC cell lines and in HNSCC lesions

DNA from exponentially growing cells was extracted and used as template to amplify by PCR the HPV genome as previously described (24). DNA was also isolated from tissue sections and used for HPV genotyping using a nested multiplex PCR protocol that combines degenerate E6/E7 consensus primers and type-specific primers, as previously reported (25). See Supplementary Material for details.

Animal studies

All animal studies were carried out according to NIH-approved protocols (ASP# 10–569), in compliance with the NIH Guide for the Care and Use of Laboratory Animals. All cell and animal handling and tumor transplantation into the animal flanks are described in detail in Supplementary Material. Briefly, all animals bearing HNSCC tumor xenografts underwent biweekly evaluation for disease onset, and the volume of the tumor lesions determined as described (23). Animals for each experiment were randomized into 3 treatment arms (20 xenografts each) consisting of daily intraperitoneal (ip) injections of rapamycin or RAD001 (5 mg/kg/d) and control diluent. Animals were euthanized at the indicated time points and tissues retrieved for histologic and immunohistochemical evaluation. See Supplementary Materials for a detailed description of all procedures used.

Tissues and immunohistochemistry analysis

For immunohistochemical analysis, samples from the Head and Neck Tissue Microarray Initiative (17) were used, containing 317 evaluable cores from formalin-fixed, paraffin-embedded cases of HNSCC. Extensive information on the Akt and mTOR pathways were used based on prior analysis (17). A detailed description of the development of a cervical cancer TMA and immunostaining techniques for Akt and mTOR pathways and \(p16\) in tissue cores and individual cases of HNSCC with known HPV infectious status is provided in Supplementary Materials.
Statistical analysis
Two-way ANOVA followed by the Bonferroni test was used to analyze the differences in xenograft tumor volumes between the 3 experimental groups for each of the 2 cell lines. Covariation of the expression of the different Akt-mTOR markers was analyzed with the non-parametric Spearman correlation (the Spearman rank correlation test). Differences in immunohistochemical reactivity between human normal tissues and HNSCC classified into different differentiation groups were analyzed by the Kruskall–Wallis test for non-Gaussian populations (nonparametric ANOVA) followed by the Dunn posttest to compare all pairs of columns (GraphPad Software). Data analysis was done with GraphPad Prism (GraphPad Software), and \( P < 0.05 \) was considered statistically significant. See Supplementary Material for additional details. The Fisher exact test was use to evaluate differences in the proportion of cases exhibiting 1% to 25%, 26% to 50%, 51% to 75%, and 76% to 100% of cells stained positive for pS6 and pAktS473 between HPV- and HPV+ HNSCC human samples. Differences in the immunoreactivity in individual HPV- and HPV+ cases and nonneoplastic oral mucosal tissues were evaluated by 1-way ANOVA. The distribution of HPV cases among different countries was evaluated using \( \chi^2 \) analysis.

Results
Incidence of HPV infection in HNSCC and cervical tumors
To begin exploring the worldwide impact of HPV-associated oral cancers, we evaluated the expression of p16, a validated surrogate marker for HPV infection in a HNSCC TMA consisting of several hundred cores of formalin-fixed, paraffin-embedded cases of HNSCC from America (Argentina, Mexico, and the United States), Africa (South Africa), and Asia (China, India, Japan, and Thailand; ref. 17). A total of 57 out of 317 cases (18%) showed a strong cytoplasmic and nuclear staining signal for p16, which was nearly homogenous throughout the malignant epithelium (Fig. 1, top, right). Higher number of p16-positive cases (p16+) WAS observed in Thailand.
and South Africa, and lower incidence was observed in China, albeit these differences were not statistically significant. In the United States, 20% of the HNSCC cases were found to be p16⁺, aligned with the current estimation of the incidence of HPV-associated HNSCC cases (26). As most cervical cancers are HPV-associated (1), we developed a cervical cancer TMA as a positive control. All but one of the cases were strongly positive for p16 (Fig. 1, bottom, left), with a pattern similar to that of the oral cancer lesions. The presence of SCC tissue was confirmed by hematoxylin and eosin (H&E; Fig. 1, top left and bottom). The data are aligned with the use of p16 as a biomarker for the detection of HPV-associated cancers (20), and hence indicate that a subset of HNSCC lesions is associated with HPV infection, irrespective of the demographic distribution of the HNSCC cases.

**Aberrant mTOR pathway activity in HPV-associated HNSCC**

mTOR is a protein kinase involved in multiple cellular functions, including cell growth promotion, which can be found as part of 2 protein complexes, mTOR complex 1 (mTORC1) and mTORC2 (27). Thus, we next correlated the expression of p16 with that of pS6 and AktS473, which are downstream phosphorylation targets of mTORC1 and mTORC2, respectively (27). The quantification of the immunostainings was used for cluster analysis to generate a heat-map, as previously described (17). The p16⁺ cluster (positive cases in red, bottom, right) highly correlated with the positive expression of pAktS473 and pS6 (Fig. 2, right). Most of the p16⁺ cases were also positive for EGFR but negative for pEGFR. The left panel shows representative immunostaining of the proteins analyzed in p16⁻ and p16⁺ lesions. These data show that most p16⁺ HNSCCs exhibit over activity of the mTOR pathway, similar to that of p16⁻ HNSCC, likely independent from the activation of EGFR. A similar broad activation of the mTOR signaling network was observed in most cases of cervical SCC (see below, Fig. 3), supporting the emerging notion that Akt-mTOR stimulation may represent an intrinsic feature of most HPV-related human carcinomas.

**Analysis of the Akt-mTOR pathway in HNSCC lesions with known HPV status**

As our data suggested an aberrant activation of the Akt-mTOR pathway in patients with HPV-associated oral cancer, we validated these results by undertaking a molecular case-control study approach using a cohort of HNSCC cases (28) or absence (n = 21) of HPV (+/−) by HPV E6 expression (25). When the cases in the 2 groups were classified based on their differentiation patterns (Supplementary Table S1), the HPV⁻ group had a higher number of well-differentiated cases whereas the HPV⁺ cohort included a higher number of poorly differentiated cases, reflecting a trend often observed in prior studies (reviewed in ref. 7). As expected, most HPV⁺ cases were distributed around the area of the base of the tongue or in the tonsil, whereas the HPV⁻ cases originated from multiple anatomic locations throughout the oral cavity, tongue, an oropharynx (Supplementary Table S2). Representative histologic images illustrate morphologic features of HPV⁺ and HPV⁻ oral tumors and specific patterns of immunoreactivity of different target proteins (Fig. 3). H&E staining show the typical features of moderately differentiated squamous cell carcinomas. In the HPV⁺ sample, p16 is strongly expressed in both nuclei and cytoplasm of the malignant cells, whereas pS6 shows essentially a cytoplasmic staining, and pAktS473 is strongly reactive in the cytoplasmic membrane. No evident differences in the distribution of the targeted Akt-mTOR pathway proteins were observed across HPV⁺ an HPV⁻ groups (Fig. 3, top). There was a near perfect correlation between the p16 staining and the presence of HPV DNA, with only 1 discordant case. In HPV⁻ lesions, all cases gave positive reaction for pS6, whereas approximately 90% of HPV⁺ cases were positive (Fig. 3, bottom, left). Further indication of an active mTOR pathway, high levels of pAktS473 were present in most HPV⁻ cases (Fig. 3, bottom, right). Some variations were observed in Akt phosphorylation, being higher in HPV⁻ (88%) than in HPV⁺ (60%) carcinomas, and S6 phosphorylation being higher in HPV⁻ cases. However, statistical analysis of the individual HPV⁻ and HPV⁺ HNSCC cases indicate that there are no significant differences in pAktS473 and pS6 staining when comparing both
groups of HNSCC, with most HNSCC lesions displaying highly elevated mTOR signaling activity when comparing with nonneoplastic oral mucosal tissue samples. Overall, we can conclude that both HPV+ and HPV-associated HNSCC exhibit an overactive mTOR pathway.

**Activation of Akt-mTOR in HPV+ HNSCC cell lines; response to rapalogs**

As the Akt-mTOR pathway was observed to be activated in HPV+ and HPV− HNSCC cases, we next investigated whether this was reflected in a representative panel of HPV+ and HPV− HNSCC derived cell lines in vitro. Initially, we analyzed the HPV status of a large collection of HNSCC cells by PCR (Fig. 4A), and this enabled the identification of 4 oral cancer cell lines, UD-SCC2, SCC47, SCC90, and 93VU47T, which were HPV+ as judged by the amplification of an HPV-specific sequence, which was observed as a DNA band of the expected size (150 bp) when compared with the positive control (HeLa cells). Glyceraldehyde-3-phosphate dehydrogenase amplification was used to show intact DNA

Figure 3. HNSCC and cervical SCCs cases were analyzed by IHC for p16, pAktS473, and pS6 expression. The figure shows a representative squamous cell carcinoma (H&E) of each group. All cervical SCC and HNSCC HPV+ cases were strongly reactive for p16 in both nuclei and cytoplasm, and this was absent in the HNSCC HPV− cases (p16). Strong immunodetection of pS6 and pAktS473, with preferential cytoplasmic and membranous distribution, respectively, were observed in both cervical SCC and HNSCC HPV+ and HPV− cases, while nonneoplastic oral mucosa shows very limited pS6 and pAktS473 immunostaining (bottom right). Quantification of IHC staining based on the percentage of stained cells in each tumoral lesion shows remarkable activation of the mTOR pathway, as reflected by the pS6 staining in a high percentage of the cervical cancers and HNSCC, the latter in both HPV+ and HPV− groups. For pAktS473, however, the fraction of immunostained cases is smaller in cervical SCC and HNSCC HPV+ lesions. The graphical representation of each individual HNSCC case (right graphs) shows that both HPV+ (n = 28) and HPV− (n = 21) exhibit a highly significant increase in pS6 and pAktS473 with respect to the levels of the phosphorylated forms of S6 and Akt in nonneoplastic oral tissues (C; n = 19 and 20, respectively). No significant differences were observed in the level of activation of Akt-mTOR pathway molecules when comparing HPV+ and HPV− HNSCC lesions (ns).
HPV of pAktS473 in HeLa but not in HNSCC cells. The Akt and mTOR pathways were significantly activated in the vast majority of the cell lines investigated, irrespective of their p16 status. Immortalized normal oral keratinocytes, NOKSI cells, representative of a normal phenotype, were used as control cells to simulate (EGF) and inhibit (EGF + LY) the Akt-mTOR pathway. C, 2 HPV-associated HNSCC and cervical cancer–derived cell lines, UDSCC2 and HeLa, respectively, were used to validate the biochemical activity of clinically relevant inhibitors allosteric mTOR inhibitors, rapamycin and RAD001, on the Akt-mTOR pathway. As seen, exposure of cells to 100 nmol/L of these inhibitors caused a time-dependent reduction in pS6 activity, with complete ablation occurring after 60 minutes of treatment, suggesting that HPV+ oral and cervical cancer cells lines are sensitive to clinically relevant rapalogs.

Rapamycin and RAD001 inhibits the growth of HPV-associated tumor xenografts

We next sought to examine whether the aberrant activation of Akt-mTOR in HPV+ oral and cervical cancers could be exploited for therapeutic purposes. For these studies, we choose UDSCC2 and HeLa cells, as representative HPV+ oral and cervical squamous cancers, respectively, which grow efficiently as tumor xenografts in athymic nude mice. We first confirmed that administration of the rapamycin and RAD001 would effectively result in the inhibition of the targeted pathways. Morphologically, UDSCC2 is a moderately differentiated squamous cell, whereas HeLa tumors display the features of a poorly differentiated cancer (Fig. 5). In both UDSCC2 and HeLa, treatment for 3 days with rapamycin and RAD001 reduced the expression levels of pS6 and pAktS473 (Fig. 5B and D). Thus, both rapalogs were able to hit their expected therapeutic molecular targets in vivo, including mTOR in its mTORC1 complex, as judged by the decrease in pS6, and likely indirectly on mTORC2, as it can be inferred from the decrease in pAktS473. Next, tumor-bearing animals were randomized and treated with vehicle control, rapamycin, or RAD001 when the average volume was approximately 200 to 250 mm3. There was a remarkable response to rapamycin and RAD001 in UMDSCC2 and HeLa cells, when compared with the corresponding control groups (Fig. 6). Indeed, statistically significant differences in tumor burden were observed as early as few days after treatment initiation. The dramatic effects of both inhibitors, as depicted in the tumor pictures, was further supported by the highly significant differences in the tumor weights of the control and treated groups at the end of the observation period (Fig. 6, bottom). Similar results were also obtained in multiple human HNSCC xenograft models derived from HPV+ HNSCC cells (23). HPV+–treated tumors are small and quiescent, with necrotic areas and strands of tumor cells without evidence of mitosis embedded into a fibrous collagen matrix. Overall, these findings suggest that
similar to HPV+ HNSCC, HPV-associated squamous tumors may respond favorably to mTOR inhibitors.

Discussion

The incidence rate of most cancer sites related to HPV infection has increased in the United States and in some European countries in the past 2 decades (7, 8). Anatomically, HPV-associated HNSCC appear to arise predominantly from the oropharynx, including base of base of tongue and tonsils (9, 30). In general, HPV+ oral cancers have a better prognosis, with increased survival and response to surgical treatment (11), radiotherapy (12, 13), and combined treatment approaches (14–16). However, HPV-positive HNSCC patients are significantly younger than those associated with traditional risk factors (8). This distinct demographic distribution may raise concerns about the potential increase in HNSCC recurrence given the longer life expectancy of HPV-associated HNSCC patients, and about the long-term consequences of exposing younger patients to radiation and aggressive cytotoxic treatments often used in HNSCC. Thus, there is an urgent need for the development and evaluation of novel molecular-targeted therapeutic approaches to treat HPV-related HNSCCs, hence reducing its morbidity and mortality, and increasing the overall patient’s quality of life. Similarly, surgery, chemoradiation with adjuvant or combination chemotherapy are the standard of care for cervical cancer patients (31, 32), highlighting the need for the development of less aggressive targeted therapeutic options. Indeed, we provide evidence that HPV-related cervical and HNSCC cases exhibit elevated mTOR function, and that clinically relevant mTOR inhibitors can decrease mTOR activity in the target tissues, thereby significantly reducing tumor burden in preclinical animal models for these HPV-associated squamous malignancies.

To begin evaluating the impact of HPV in HNSCC worldwide, we immunostained and quantified the expression of p16, which has been recognized as a reliable surrogate marker for high-risk HPV infection (20). This protein is encoded by the CDKN2A (MTS1, INK4A) tumor suppressor gene and inactivates the function of cdk4- and cdk6-cyclin D complexes, thereby regulating cell proliferation by preventing the inactivation of the retinoblastoma tumor suppressor protein (pRb) by hyperphosphorylation (33). In tumors

![Figure 5. Excised tumors from athymic mice treated for 3 days with rapamycin, RAD001 or control diluent, were processed for histologic evaluation. A, UDSCC2 tumors grow in control treated animals (top) as moderately differentiated squamous cell carcinomas, with solid sheets of cells occasionally forming keratinized clumps of cells. In animals treated with rapamycin or RAD001, edema and areas of initial tissue disruption were observed (top, middle and right). The expression of both pS6 and pAktS473 was significantly decreased by treatment with both mTOR inhibitors, as seen in individual tissues by IHC (A, middle and bottom row) and the quantification of multiple treated tumors (B). C, a very similar profile was observed with HeLa xenografts, which are poorly differentiated squamous cell carcinomas (left). The treated tumors showed features similar to those described for UDSCC2 (top, middle and right). A decrease in the expression of pS6 and pAktS473 is evident upon treatment with both mTOR inhibitors (C, middle and bottom row) as further confirmed by quantification of the immunoreactions (D). (***, P < 0.001; ***, P < 0.001).]
with biologically active HPV, E7 protein forms complexes with hypophosphorylated forms of the pRb, resulting in a decrease of the cellular pRb level and a release of E2F, a transcription factor involved in cell-cycle progression (34). In these tumors, the inactivation of pRb by HPV E7 protein may lead to p16 overexpression because Rb normally represses p16 transcription (35). Alternatively, the high-risk HPV E7-mediated increased expression of the histone demethylases KDM6A and KDM6B may result in derepression of p16 gene transcription, thus resulting in high levels of p16 (36). Hence, p16 immunohistochemistry (IHC) is considered comparable or even superior to in situ hybridization for the detection of high-risk HPV (18). However, negative p16 staining have also been described in HPV+ tumors due to allelic loss and/or promoter hypermethylation (37), which might explain a single case of cervical SCC that was negative for p16. In HNSCC, approximately 18% of all cases from a large international collection of HNSCC lesions were p16+, suggesting that the impact of HPV-infection in oral cancer has reached a worldwide proportion. Among the tissues analyzed, the cases from South Africa and Thailand had a higher percentage of HPV-positive cases, with cases from China being the lowest. Although these differences among countries did not reach statistical significance, likely due to the limited number of HPV+ cases for some of the geographic regions, these findings suggest the existence of distinct regional- and country-specific rates of HPV-related oral malignancies. This possibility may need to be investigated further, aiming at implementing appropriate preventing and treatment strategies.

The mTOR-regulated molecular network coordinates mitogenic signaling with nutrient-sensing pathways thereby controlling protein translation and synthesis.
autophagy, cellular metabolism, and cell migration (27). This pathway is often initiated by growth factor- or oncogene-induced activation of PI3K, and the consequent activation of Akt upon its phosphorylation in threonine 308 by the PI3K-dependent stimulation of a kinase known as PDK1 (27). Active, pAktT308 then phosphorylates and inactivates a tumor-suppressor protein, tuberous sclerosis complex protein 2 (TSC2), which suppresses the function of the small GTPase Rheb1. This inactivation of TSC2 by Akt leads to the accumulation of the active Rheb1, which in turn promotes the activation of mTOR in its complex mTORC1. mTORC1 then phosphorylates p70-S6 kinase (p70S6K, S6K), which phosphorylates ribosomal protein S6, leading to the accumulation of pS6 (27). Amino acid and metabolic-regulated circuities stimulate mTOR in its complex mTORC2, which phosphorylate multiple protein targets, including Akt in its serine 473, resulting in increased pAktS473 (27). In this context, the molecular mechanisms resulting in increased activation of mTOR by HPV are at the present not fully understood. High-risk E6 causes the rapid degradation of TSC2, resulting in TORC1 activation (38). In stable HPV-infected cells, however, the levels of TSC2 are not greatly affected (39). In line with this, we did not observe consistent changes in TSC2 expression in HPV+ HNSCC cell lines (not shown). Of interest, HeLa cells are defective in the tumor suppressor protein LKB1 (40), also known as STK11, which inhibits mTOR by a pathway impinging on TSC2 stimulation (41). Thus, we can speculate that in addition of persistent expression of high-risk HPV E6 and E7 proteins, additional genetic and epigenetic events resulting in mTOR activation may be required for the development of HPV-related malignancies. In this regard, most HPV+ lesions do not express elevated levels of phosphorylated, active EGFR (see Fig. 2), and while a fraction of HNSCC harbor activating mutations in PI3K, no mutations in PI3K were identified in the HPV+ HNSCC cell lines used in this study (not shown). Preliminary data, however, suggest that nearly 30% of the HPV+ cases may exhibit reduced expression of the tumor suppressor protein PTEN, which is a lipid phosphatase counteracting phosphatidylinositol (3,4,5)-trisphosphate accumulation by PI3K (42). Thus, while additional studies may be required to confirm the contributing role of PTEN and other candidate oncogenic and tumor suppressive molecules regulating mTOR in HPV-associated malignancies, we can conclude that activation of the mTOR pathway represents a common feature of nearly all HPV-associated cervical and oral SCCs, an observation that can now be exploited for therapeutic strategies.

mTORC1 is activated in most HPV-associated SCCs, including oral and cervical carcinomas, as judged by readily detection of accumulated pS6. About cervical SCCs, this observation is aligned with prior reports describing the presence of phosphorylated p70S6 kinase in cervical SCCs (43), although pS6 seems to be a more reliable marker to document TORC1 activation by IHC than its upstream kinase p70S6K (44). However, fewer HPV+ HNSCC cases were positive for pAktS473 than HPV− HNSCC lesions, 60% and 88% of the cases, respectively. This difference was even more dramatic in cervical SCCs, as only approximately (60%) were stained positive for pAktS473, even if most of these HPV-associated lesions exhibit elevated pS6. This information has significant implications, as it suggests that HPV+ SCC cases have more limited activation of mTORC2 than mTORC1 and hence may be more dependent for their growth of the mTORC1. Indeed, we observed that xenografts of HPV+ SCC cells are highly sensitive to allostatic inhibitors of mTORC1, rapamycin and RAD001, thus supporting their preclinical efficacy of targeting mTOR in these tumor lesions.

On the other hand, blockade of mTORC1 in vitro resulted in the fast increase of pAktS473 in cervical but not oral SCC-derived cells. The reason for this notable difference is unclear. In this regard, the disruption of negative feedback loops by rapalogs has been reported, which may result in Akt activation (45). However, we did not observe an increase in the level of pAktT308, which represents the active form of Akt (27). Thus, as we and others have previously reported, HNSCC cells do not exhibit an increase in Akt activity after mTORC1 inhibition with rapamycin, perhaps a distinct property that may contribute to its potential clinical efficacy (23, 46). The transient activation of the mTOR mTORC2 complex, which phosphorylates Akt in serine 473 (27), in HeLa cells may require further exploration. Nonetheless, both rapalogs, rapamycin and RAD001, caused a clear reduction in pAktS473 in vivo, suggesting that prolonged inhibition of mTORC1 may result in mTORC2 inhibition, as reported in HPV+ HNSCC xenografts (23), in HNSCC patients treated with a rapamycin prodrug, CCI-779 (47), and in certain cellular systems (48).

Of interest, our emerging results suggest that the inhibition of mTOR by rapamycin and RAD001 may result in potential therapeutic benefit in HPV+ HNSCC as well as in HPV+ oropharyngeal and cervical SCCs. Indeed, both rapalogs had a remarkable antitumor activity when evaluated in HPV− xenograft models (23) as well as when HPV16+ oral cancer and HPV18+ cervical cancer cells were xenografted in mice. Overall, our present observations may provide a strong rationale for the clinical evaluation of rapalogs in management of HPV-associated malignancies. Specifically in the case of oral cancer, the clinical consequences of radiation and chemotherapy and their combinations are usually associated with significant side effects that result in a poor quality of life and severe chronic functional problems that have proven difficult to address, including dysphagia, xerostomia, feeding-tube dependency from fibrosis and scarring of the pharyngeal muscles, chronic aspiration, and chronic fatigue. These side effects are not known to be associated with mTOR inhibitors (49). Thus, we can envision that mTOR-blocking agents may represent a promising therapeutic approach in HPV+ oral and cervical cancers, as a single agent in a neoadjuvant setting, to lower the dose of radiation/chemotherapy required for local control, or after conventional surgical excision of the tumor with or without chemoradiation, to prevent or delay tumor recurrence.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Grant Support
This work was supported by the Intramural Research Program of the NIH, National Institute of Dental and Craniofacial Research, project Z01DE005558. T. Seiwert was supported by a Flight Attendant Medical Research Institute Young Clinical Scientist Award (FAMRI YCSA). N. Gangane was supported by a Yamagiwa-Yoshida fellowship from the Union for International Cancer Control, International cancer technology transfer fellowships (ICRET).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 3, 2011; revised January 29, 2012; accepted February 20, 2012; published OnlineFirst March 12, 2012.

References

mTOR as a Molecular Target in HPV-Associated Oral and Cervical Squamous Carcinomas

Alfredo A. Molinolo, Christina Marsh, Mohamed El Dinali, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-11-2824

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2012/03/12/1078-0432.CCR-11-2824.DC1

Cited articles
This article cites 48 articles, 18 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/18/9/2558.full#ref-list-1

Citing articles
This article has been cited by 10 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/18/9/2558.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://clincancerres.aacrjournals.org/content/18/9/2558.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.